Study details
Enrolling now
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
University of Florida
NCT IDNCT06488222ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
34
Study length
about 2.8 years
Ages
18+
Locations
1 site in FL
What this study is about
This trial is testing a treatment of intravesical gemcitabine and docetaxel in people with low grade intermediate risk bladder cancer. The goal is to see if this treatment helps decrease disease recurrence.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Docetaxel
- 2.Take Gemcitabine
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IVInjection / IV
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
docetaxel, gemcitabine
Drug routes
infusion, injection (Injection)
Endpoints
Primary: Recurrence free survival
Body systems
Oncology